Anidulafungin versus Fluconazole for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis. METHODS: Adults with invasive candidiasis were randomly assigned to receive either intravenous anidulafungin or intravenous fluconazole. All patients could receive oral fluconazole after 10 days of intravenous therapy. The primary efficacy analysis assessed the global response (clinical and microbiologic) at the end of intravenous therapy in patients who had a positive baseline culture. Efficacy was also assessed at other time points. RESULTS: Eighty-nine percent of the 245 patients in the primary analysis had candidemia only. Candida albicans was isolated in 62% of the 245 patients. In vitro fluconazole resistance was infrequent. Most of the patients (97%) did not have neutropenia. At the end of intravenous therapy, treatment was successful in 75.6% of patients treated with anidulafungin, as compared with 60.2% of those treated with fluconazole (difference, 15.4 percentage points; 95% confidence interval [CI], 3.9 to 27.0). The results were similar for other efficacy end points. The statistical analyses failed to show a "center effect"; when data from the site enrolling the largest number of patients were removed, success rates at the end of intravenous therapy were 73.2% in the anidulafungin group and 61.1% in the fluconazole group (difference, 12.1 percentage points; 95% CI, -1.1 to 25.3). The frequency and types of adverse events were similar in the two groups. The rate of death from all causes was 31% in the fluconazole group and 23% in the anidulafungin group (P=0.13). CONCLUSIONS: Anidulafungin was shown to be noninferior to fluconazole in the treatment of invasive candidiasis. (ClinicalTrials.gov number, NCT00056368 [ClinicalTrials.gov]).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
In the citing paper
“A randomized controlled trial, more robust for examining effects of treatment, found superior outcomes for patients who received an echinocandin as primary treatment for invasive candidiasis [12].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [12]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Self-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Self-citationSecular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Self-citationTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Self-citationRex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495
Self-citationPark, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Research works printed but not linked: 4
- Graybill JR, 2001, Curr Opin Investig Drugs, 2, 468
- Espinel-Ingroff A, 2003, Rev Iberoam Micol, 20, 121
- Park S, Paderu P, Perlin DS. Amino acid polymorphisms in Fks1 from C. parapsilosis, C. metapsilosis and C. orthopsilosis strains account for intrinsic reduced susceptibility to echinocandin drugs. In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006.
- 10.1002/(SICI)1097-0258(19960830)15:16<1729::AID-SIM334>3.0.CO;2-M · doi:10.1002/(sici)1097-0258(19960830)15:16<1729::aid-sim334>3.0.co;2-m
Cited by
Items 501–600 of 892
Utility of Antifungal Susceptibility Testing and Clinical Correlations
Diekema, D. J., & Pfaller, M. A. (2011) · Humana Press eBooks · doi:10.1007/978-1-59745-134-5_8 · Cited by 10
Use of antifungal drugs in hematology
Nucci, M. (2012) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.5581/1516-8484.20120095 · Cited by 10
“The main indication of the echinocandins is primary treatment of candidemia and invasive candidiasis(13,34-37).”
BackgroundActualización en terapia antifúngica: nuevos fármacos e indicaciones
Fortün, J. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(11)70042-8 · Cited by 17
Influence of Serum and Albumin on Echinocandin In Vitro Potency and Pharmacodynamics
Nasar, A., Ryan, L., Frei, C. R., Cota, J. M., & Wiederhold, N. P. (2013) · Current Fungal Infection Reports · doi:10.1007/s12281-013-0136-z · Cited by 11
Utilidad clínica de la micafungina en el tratamiento de las candidiasis invasoras en el neonato
Infante-López, M. E., & Rojo‐Conejo, P. (2009) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(09)70009-9 · Cited by 8
[Nosocomial candidemia: new challenges of an emergent problem].
Gómez, J. G., Vázquez, E. G., Hernández, A., Espinosa, C., & Pardo, J. R. (2010) · PubMed · Cited by 20
Antifungal pharmacodynamics: Latin America's perspective
González, J. M., Rodríguez, C. A., Agudelo, M., Zuluaga, A. F., & Vesga, Ó. (2016) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2016.09.009 · Cited by 13
Junco, S. J., Chehab, S., Giancarelli, A., Bowman, M. C., & Turner, R. B. (2021) · Infectious Diseases Research and Treatment · doi:10.1177/11786337211018722 · Cited by 10
“Hospital length of stayb 22 (12-35) 29 (20-53) .”
Update: invasive Pilzinfektionen
Lichtenstern, C., Swoboda, S., Hirschburger, M., Domann, E., Hoppe‐Tichy, T., Winkler, M., Lass‐Flörl, C., & Weigand, M. A. (2010) · Der Anaesthesist · doi:10.1007/s00101-009-1655-4 · Cited by 12
When and How to Cover for Fungal Infections in Patients with Severe Sepsis and Septic Shock
Allou, N., Allyn, J., & Montravers, P. (2011) · Current Infectious Disease Reports · doi:10.1007/s11908-011-0204-x · Cited by 10
“Despite the above limitations for several drugs, the efficacy of amphotericin B, triazoles and echinocandins in randomized controlled trials in patients with C/IC appears to be fairly similar [18, 36, 38, 39, 46, 47].”
BackgroundTreatment strategies for central venous catheter infections
Sabatier, C., Ferrer, R., & Vallés, J. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903133819 · Cited by 10
New developments in the antifungal susceptibility testing of Candida
Pfaller, M. A. (2008) · Current Fungal Infection Reports · doi:10.1007/s12281-008-0019-x · Cited by 10
Clinical indications for newer antifungal agents
Murphy, N. N., & Pile, J. C. (2009) · Journal of Hospital Medicine · doi:10.1002/jhm.412 · Cited by 9
“Caspofungin was better tolerated than D-AmB, and the authors concluded that caspofungin was at least as effective as DAmB, with fewer adverse effects.5 A 2007 study randomized invasive candidiasis patients to micafungin or L-AmB, and reported similar efficacy in both arms, with less drug-related adverse events in the…”
BackgroundResultInfluentialRecurrent candidaemia and pacemaker wire infection with Candida albicans
Glöckner, A. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02139.x · Cited by 9
Knowledge gaps in candidaemia/invasive candidiasis in haematological cancer patients
Colombo, A. L., Agnelli, C., & Kontoyiannis, D. P. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa446 · Cited by 10
Störzinger, D., Lichtenstern, C., Swoboda, S., Weigand, M. A., & Hoppe‐Tichy, T. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01573.x · Cited by 8
Norimatsu, Y., Morii, D., Kogure, A., Hamanaka, T., Kuwano, Y., Yokozawa, T., & Oda, T. (2017) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2017.03.002 · Cited by 8
Accounting for center-level effects in multicenter randomized controlled trials
Islam, S., & Bangdiwala, S. I. (2024) · Trials · doi:10.1186/s13063-024-08202-w · Cited by 10
“Only a few authors have discussed and emphasized the importance of accounting for the central effect in a multicenter randomized controlled trial [9, 13], but our literature review in the New England Journal of Medicine (NEJM) and The Lancet showed that a very small proportion of trials considered…”
BackgroundMethodCatheter-Related Bloodstream Infections Review
Abebe, A., Tener, M., Waller, S. C., & Atrouni, W. E. (2013) · Hospital Medicine Clinics · doi:10.1016/j.ehmc.2013.08.002 · Cited by 10
Potshangbam, A. M., Rathore, R. S., Prabhu, N. P., & Vindal, V. (2016) · SpringerPlus · doi:10.1186/s40064-016-2589-3 · Cited by 8
“The mode of action of echinocandins perhaps makes this particular class of compounds one of the most effective antifungal agents with minimal collateral toxicity in mammalian cells (Reboli et al. 2007).”
BackgroundCháves, F., Garnacho‐Montero, J., del Pozo, J. L., Bouza, E., Capdevila, J. A., de Cueto, M., Domínguez, M. Á., Esteban, J., Fernández‐Hidalgo, N., Sampedro, M. F., et al. (2018) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2017.09.001 · Cited by 15
Lee, S.-C., Lee, C., Shih, H.-J., Huang, S.-H., Chiou, M., & See, L. (2013) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2013.09.006 · Cited by 8
“The loading dose of caspofungin was 70 mg followed by a maintenance dose of 50 mg intravenously once daily for 1e4 weeks.(9,10,20) In the case of micafungin, there was no loading dose and a maintenance dose of 100 mg intravenously was given once daily for 1e4 weeks.”
MethodResultAdvances in antifungal prophylaxis and empiric therapy in patients with hematologic malignancies
Murali, S., & Langston, A. A. (2009) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2009.00441.x · Cited by 9
Invasive fungal disease: better survival through early diagnosis and therapeutic intervention
Maschmeyer, G. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.11 · Cited by 9
Recomendações no manejo das complicações infecciosas no transplante de células-tronco hematopoéticas
Garnica, M., Machado, C. M., Cappellano, P., Carvalho, V. V. H., Nicolato, A., da Cunha, C. A., & Nucci, M. (2010) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1590/s1516-84842010005000026 · Cited by 18
Hidayathulla, S., Shahat, A. A., Alsaid, M. S., & Al-Mishari, A. A. (2018) · FEMS Microbiology Letters · doi:10.1093/femsle/fny051 · Cited by 8
“This antifungal drug functions by destabilizing the fungal cell wall and inhibiting the synthesis of glucan, a cell wall integral component (Reboli et al. 2007).”
BackgroundRosa, F. G. D., Busca, A., Capparella, M. R., Yan, J. L., & Aram, J. A. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01024-7 · Cited by 9
“6% at EOIVT) in patients with IC in the registrational study [24].”
BackgroundUpdate on New Antifungal Therapy
Juang, P. (2007) · AACN Advanced Critical Care · doi:10.1097/01.aacn.0000284425.71083.30 · Cited by 8
Actividad antifúngica in vitro de la anidulafungina
Quindós, G., & Eraso, E. (2008) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(08)70025-1 · Cited by 8
“Candida albicans AND 4073 0’03-2 0’03 [22,39,50,52,55,71]”
BackgroundInfluentialMachado, E., Rocha, J., Coque, T., Cantón, R., Sousa, J. C., Sousa, H., & Peixe, L. (2008) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 8
La escritura en la enseñanza secundaria: los procesos del pensar y del escribir
Björk, L. A., & Blomstrand, I. (2000) · Graó eBooks · Cited by 46
Reboli, A. C. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu160 · Cited by 8
Self-citationLin, S., Huang, H., Chang, L., Wang, Y., Chen, T., Chang, K., Tu, H., & Lu, P. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.03.023 · Cited by 9
An Update on Recent Clinical Trial Data in Bloodstream Infection
Stewart, A. G., Simos, P., Sivabalan, P., Escolà‐Vergé, L., Garnham, K., & Isler, B. (2024) · Antibiotics · doi:10.3390/antibiotics13111035 · Cited by 9
Lodise, T. P., Garey, K. W., Aram, J. A., Nathanson, B. H., & Redell, M. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf472 · Cited by 8
Dib, R. W., Hachem, R. Y., Chaftari, A., & RAAD, I. I. (2018) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2018.028 · Cited by 8
“Some studies relied on the hemodynamic status and microbiologic eradication, while others relied on the improvement in clinical signs and symptoms (defervescence for 24 hours) along with microbiological eradication.(14,15)”
MethodClinical Syndromes: Candida and Candidosis
Ruhnke, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-92300-0_4 · Cited by 8
Caspofungin for the treatment of candidaemia in patients with haematological malignancies
Pagano, L., Fianchi, L., Fanci, R., Candoni, A., Caira, M., Posteraro, B., Morselli, M., Valentini, C. G., Farina, G., Mitra, M. E., et al. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02832.x · Cited by 7
Almeida, B., Breda, G. L., Queiroz‐Telles, F., & Tuon, F. F. (2014) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2014.952246 · Cited by 7
Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections?
Tapısız, A. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.7 · Cited by 8
Anidulafungin and its role in candida infections
Cappelletty, D. M., & Jung, R. (2009) · Infection and Drug Resistance · doi:10.2147/idr.s4796 · Cited by 8
“The second study was a randomized, prospective, noninferiority study comparing anidulafungin to fluconazole for candidemia or invasive candidiasis.(60) Patients aged 16 to 91 years received either 200 mg on day 1 followed by 100 mg once daily of anidulafungin or 800 mg on day 1 followed by 400 mg once daily of flucona…”
Salas, V., Pastor, F., Calvo, E., Mayayo, E., Quindós, G., Carrillo, A. J., & Guarro, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00500-11 · Cited by 7
“parapsilosis (16, 19), some controversy exists about the usefulness of echinocandins in the treatment of disseminated infections caused by that fungus.”
BackgroundPharmacotherapy of Candida Infections with Echinocandins
Espinel-Ingroff, A. V., Canton, E., Martín‐Mazuelos, E., & Pemán, J. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2311 · Cited by 7
Complications of invasive mycoses in organ transplant recipients
Samanta, P., & Singh, N. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2016.1242412 · Cited by 8
“larly beneficial in the critical care unit setting as they reduced the intensive care unit and overall hospital stay [41,45].”
BackgroundCojutti, P. G., Lugano, M., Righi, E., Rocca, G. D., Bassetti, M., Hope, W. W., & Pea, F. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2526-1 · Cited by 9
Schneeweiß, S., Carver, P. L., Datta, K., Galar, A., Johnson, M. D., Letourneau, A. R., Marty, F. M., Nagel, J. L., Najdzinowicz, M., Saul, M. I., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz396 · Cited by 8
Management of Multidrug Resistant Infections in Lung Transplant Recipients with Cystic Fibrosis
Vazirani, J., Crowhurst, T., Morrissey, C. O., & Snell, G. I. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s301153 · Cited by 7
“Randomized trials support the treatment for invasive candidemia typically with echinocandin therapy (anidulafungin or caspofungin) over fluconazole amphotericin B.(83,84) Non-neutropenic patients who are not critically unwell and unlikely to have fluconazole resistant organisms (eg, C.”
Background[Recommendations of antifungal treatment in patients with low grade immunosuppression].
Barberán, J., Mensa, J., Fariñas, C., Llinares, P., Serrano, R., Menéndez, R., Agustí, C., Gobernado, M., Azanza, J. R., & Rodríguez, J. A. G. (2008) · PubMed · Cited by 19
Cisneros, J. M., Neth, O., & Pachón, J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis524 · Cited by 7
Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy
Sterling, J. A. (2007) · Hospital Pharmacy · doi:10.1310/hpj4206-578 · Cited by 7
Clinical impact of fluconazole-resistant Candida parapsilosis : a narrative review
Bartalucci, C., Vena, A., Giacobbe, D. R., & Bassetti, M. (2025) · Future Microbiology · doi:10.1080/17460913.2025.2544443 · Cited by 9
De-escalation from Echinocandins to Azole Treatment in Critically Ill Patients with Candidemia
Lin, J., Zhou, M., Chen, J., Zhang, L., Lu, M., & Liu, Z. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.04.044 · Cited by 6
González, M. C., & González, J. C. M. (2008) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(08)70026-3 · Cited by 11
Updated guidelines for managing fungal diseases in hematology patients
Hicheri, Y., Toma, A., Maury, S., Pautas, C., Mallek, H., & Cordonnier, C. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.85 · Cited by 10
Adequate duration of therapy in severe fungal infections
Bassetti, M., Giacobbe, D. R., Berruti, M., Puente, F. D., & Vena, A. (2020) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000758 · Cited by 6
A Case of Candidemia after Long-term Presence of Urethral Foreign Bodies
Nagata, J., Kawasaki, T., Iesato, K., Sugiura, T., Yamauchi, K., Tsuyusaki, J., Fujimura, M., Kuroda, F., Mikami, K., Dudek, S. M., et al. (2021) · IDCases · doi:10.1016/j.idcr.2021.e01176 · Cited by 7
Kraft, L., Ribeiro, V. S. T., Gonçalves, G. A., Suss, P. H., & Tuon, F. F. (2022) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2022.07.002 · Cited by 6
In Vitro Susceptibility of Candida Isolates from Organ Transplant Recipients to Newer Antifungals
Geusau, A., Antoniewicz, L., Poitschek, C., Presterl, E., & Willinger, B. (2014) · Mycopathologia · doi:10.1007/s11046-014-9738-4 · Cited by 6
“parapsilosis, ANID showed no advantage over fluconazole [16].”
BackgroundMontejo, M., & Quindós, G. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(11)70004-0 · Cited by 8
Equinocandinas: aspectos aplicados de la farmacología
Perea, J. R. A. (2016) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2016.02.004 · Cited by 10
Has the Optimal Therapy for Invasive Candidiasis Now Been Defined?
Andes, D. R. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy830 · Cited by 6
Wattier, R. L., & Steinbach, W. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40181-4.00293-0 · Cited by 6
Bal, A. M. (2020) · Mycoses · doi:10.1111/myc.13196 · Cited by 6
Candida glabratafungaemia at an Australian cancer centre: epidemiology, risk factors and therapy
Trubiano, J. A., Leung, V. K. Y., Worth, L. J., Teh, B. W., Thursky, K., & Slavin, M. A. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1023724 · Cited by 6
Deep-seated Candida infections in the intensive care unit
Brusselaers, N., Blot, S. I., & Vogelaers, D. (2011) · Ghent University Academic Bibliography (Ghent University) · Cited by 9
Empiric anti-Candida therapy for patients with sepsis in the ICU: how little is too little?
Golan, Y. (2009) · Critical Care · doi:10.1186/cc7977 · Cited by 8
“glabrata isolates are treatable by fluconazole when administered at the dose used in Zilberberg and colleagues’ analysis [9-10].”
MethodAnidulafungin compared with fluconazole therapy in critically ill patients
Kett, D. H., Shorr, A., Reboli, A., Reisman, A., Biswas, P., & Schlamm, H. T. (2010) · Critical Care · doi:10.1186/cc8304 · Cited by 6
Self-citationAnidulafungin and Fluconazole for Candidiasis
Aberegg, S. K., & O’Brien, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmc071981 · Cited by 6
Candidemia in the ICU: Does Initial Antifungal Matter?*
Bennett, J. E., & Powers, J. H. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000002903 · Cited by 6
Update on Antifungal Resistance in Children: Epidemiology and Recommendations
Verweij, P. E., & Warris, A. (2013) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31828745b2 · Cited by 5
Antifungal Therapy in Eye Infections: New Drugs, New Trends
Joseph, J., & Sharma, S. (2016) · Springer eBooks · doi:10.1007/978-81-322-2782-3_9 · Cited by 8
Opciones terapéuticas para el tratamiento antifúngico en el paciente crítico
Zaragoza, R., & Pemán, J. (2012) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2012.03.009 · Cited by 10
Does the current treatment of invasive fungal infection need to be reviewed?
Martín‐Peña, A., Aguilar‐Guisado, M., & Cisneros, J. M. (2013) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2013.02.008 · Cited by 7
Pemán, J., & Almirante, B. (2008) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13128779 · Cited by 10
Puesta al día en la candidiasis invasora en el paciente crítico no neutropénico
Zaragoza, R., Ramírez, P., Borges-Sa, M., & Pemán, J. (2016) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2016.03.001 · Cited by 8
Shoham, S., Groll, A. H., & Walsh, T. J. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-04579-7.00149-0 · Cited by 6
Self-citationAsai, N., Sakanashi, D., Suematsu, H., Kato, H., Hagihara, M., Shiota, A., Koizumi, Y., Yamagishi, Y., & Mikamo, H. (2020) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2020.11.003 · Cited by 5
Gebretekle, G. B., Fentie, A. M., Gebremariam, G. T., Ali, E. E., Erku, D., Alemayehu, T., Abebe, W., & Sander, B. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08662-3 · Cited by 7
“clinical and microbiological success) with no need for additional systemic antifungal therapy [20].”
BackgroundInfluentialNeofytos, D., Steinbach, W. J., Hanson, K. E., Carpenter, P. A., Papanicolaou, G. A., & Slavin, M. A. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.01.011 · Cited by 5
Evaluation of catheter related bacteremia in patients with end stage renal disease on hemodialysis
Manuti, J. K., Saadoon, A. M., Jawad, T. S., & Alawn, A. G. (2023) · Journal of Clinical Nephrology · doi:10.29328/journal.jcn.1001105 · Cited by 5
Karthaus, M., & Hentrich, M. (2010) · Mycoses · doi:10.1111/j.1439-0507.2010.01978.x · Cited by 5
Issues in the design and interpretation of antifungal drug trials in the critically ill
Ostrosky-Zeichner, L. L. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328331fc5f · Cited by 6
Treatment of invasive fungal infections
Bellmann, R., & Weiler, S. (2011) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-011-0290-3 · Cited by 5
Chandrasekar, P. H., & Ljungman, P. T. (2008) · Transplantation · doi:10.1097/tp.0b013e318177de64 · Cited by 7
“Anidulafungin has demonstrated efficacy in the treatment of invasive candidiasis (94), but data evaluating the early use of anidulafungin in patients at high-risk are limited.”
BackgroundPapel de la anidulafungina en el paciente con trasplante de órgano sólido
Aguado, J. M., & Ayats, J. (2008) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(08)76590-x · Cited by 5
Candida bloodstream infection: A clinical microbiology laboratory perspective
Pongrácz, J., & Kristóf, K. (2014) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/amicr.61.2014.3.11 · Cited by 4
“pared to other species with lower MICs, which is probably in connection with the low virulence of the species [35, 36].”
BackgroundTolérance de la caspofongine chez les patients de réanimation : étude prospective
Constantin, J.-M., Roszyk, L., Guerin, R., Bannier, F., Chartier, C., Perbet, S., Futier, E., Cayot-Constantin, S., Sapin, V., & Bazin, J.-É. (2008) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/j.annfar.2008.06.013 · Cited by 5
Pérez-Blázquez, E. (2009) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(09)70014-2 · Cited by 5
Assessment of antifungal effect of omeprazole on Candida Albicans
kaslan, F. K. C. U. (2013) · International Journal for Biotechnology and Molecular Biology Research · doi:10.5897/ijbmbr2013.0157 · Cited by 5
“Beil and Sewing have reported that omeprazole inhibited the (H+K)-ATPase activity of preparations isolated from parietal cells of guinea pig (National Committee for Clinical Laboratory Standards, 1997; Reboli et al., 2007).”
BackgroundInfluentialÉpidémiologie des candidoses invasives en France
Charles, P., Large, A., Quenot, J., & Dalle, F. (2016) · Réanimation · doi:10.1007/s13546-016-1183-6 · Cited by 5
Actualización sobre el tratamiento de las infecciones fúngicas graves
Guerra, M. (2008) · Revista española de quimioterapia. Suplemento · Cited by 7
Cortés, J. A., & N, J. A. R. (2011) · Revista chilena de infectología · doi:10.4067/s0716-10182011000700004 · Cited by 17
Approach to the Diagnosis and Management of Infected Pancreatic Necrosis: A Narrative Review
Sahu, S. K., Giri, S., Das, S., Patro, C. D., Praharaj, D. L., Mallick, B., Nath, P., Panigrahi, S. C., & Anand, A. C. (2025) · Cureus · doi:10.7759/cureus.83020 · Cited by 4
“Thus, for patients with fungemia or culture-positive fungal infections, echinocandins are recommended over azoles, even if they are azole-sensitive [30].”
Theodore, D., Henneman, A. D., Loo, A. S., Shields, R. K., Eschenauer, G. A., Sobieszczyk, M. E., & Kubin, C. J. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae175 · Cited by 5
Caniff, K. E., Musawa, M. A., Judd, C., Shupp, M., Veve, M. P., Alangaden, G. J., Claeys, K. C., Scipione, M. R., Walsh, T. J., & Rybak, M. J. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.00043-25 · Cited by 5
“The majority of patients included in this study received directed treatment with an echinocandin agent, which could perhaps offer some survival benefit regardless of baseline illness severity or slight delays in treatment initiation (46, 47).”
Self-citationVahedi‐Shahandashti, R., Moroder, E., & Lass‐Flörl, C. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00241-25 · Cited by 5
“With the introduction of echinocan dins for managing invasive candidiasis, these agents have become the preferred first-line therapy of invasive candidiasis for adult patients (1, 29), showing efficacy comparable to fluconazole in randomized, comparative clinical trials (29).”
Logan, C., Allebone-Salt, P. E., Mazzella, A., Hemsley, C. J., Goodman, A. L., Ward, C., Fife, A., Schelenz, S., Abdolrasouli, A., & Bicanic, T. A. (2026) · Journal of Infection · doi:10.1016/j.jinf.2026.106692 · Cited by 7
Management of invasive candidiasis in nonneutropenic ICU patients
Weiss, E., & Timsit, J. (2014) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936114562586 · Cited by 7
“This was based on a great number of clinical trials evaluating fluconazole in this indication [Anaissie et al. 1996; Rex et al. 1994; Reboli et al. 2007].”
Fresenius, M. (2014) · Springer eBooks · doi:10.1007/978-3-642-44933-8_11 · Cited by 4
Hasan, M. J., Neelotpol, S., & Rabbani, R. (2022) · The Journal of Critical Care Medicine · doi:10.2478/jccm-2022-0006 · Cited by 4
“In vitro data showed that anidulafungin is less potent against Candida parapsilosis isolates [43-45] but, it is more potent to this species than caspofungin and micafungin [46].”
Background
Metadata
- Authors
- Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., Krause, D. S., & Walsh, T. J.
- Affiliations
- Cooper University Hospital (US)
- Hamilton Health Sciences (CA)
- University of Alabama at Birmingham (US)
- University of Mississippi (US)
- University of Miami (US)
- University Health Network (CA)
- University of Rochester (US)
- Vifor Pharma (Germany) (DE)
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-14
- Volume
- 356
- Issue
- 24
- Pages
- 2472-2482
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126319933
- Cited by
- 894
- References
- 27
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 21 · 2023: 33 · 2022: 23 · 2021: 37 · 2020: 47 · 2019: 34 · 2018: 40 · 2017: 29 · 2016: 34 · 2015: 44 · 2014: 46 · 2013: 55 · 2012: 52
- FWCI
- 58.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Eli Lilly and Company
- Pfizer
- Viropharma
- Astellas Pharma
- Basilea Pharmaceutica
- Duke Clinical Research Institute
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- anidulafungin, fluconazole, invasive candidiasis, echinocandins, candidemia, Candida albicans, non-inferiority, antifungal therapy, mortality, fluconazole resistance
- MeSH terms
- Anidulafungin, Adolescent, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida, Candidiasis, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Peptides, Cyclic, Fluconazole, Fungemia, Treatment Outcome, Kaplan-Meier Estimate, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.